menu
    • menu
    [{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Julius Clinical | Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Julius Clinical | Amsterdam UMC, VUmc","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Julius Clinical | Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Alzheimer's Disease Cooperative Study | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Alzheimer's Disease Cooperative Study | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Alzheimer's Disease Cooperative Study | National Institute on Aging"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience | Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Nordic Bioscience | Amsterdam UMC, VUmc","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Nordic Bioscience | Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivoryon Therapeutics \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Vivoryon Therapeutics \/ Covance"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Hauck Aufh\u00e4user Lampe Privatbank AG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Nordic Bioscience"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Yorkville","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Nephrology","graph2":"Phase I","graph3":"Vivoryon Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Yorkville","highestDevelopmentStatusID":"6","companyTruncated":"Vivoryon Therapeutics \/ Yorkville"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Koch Wertpapierhandels GmbH","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Varoglutamstat","moa":"QPCT\/QPCTL","graph1":"Nephrology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Koch Wertpapierhandels GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Koch Wertpapierhandels GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Vivoryon Therapeutics

    Menu

    Vivoryon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Koch Wertpapierhandels GmbH

                            Deal Size : $5.9 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vivoryon Successfully Completes Private Placement Raising EUR 5.1 Million

                            Details : The collaboration aims to advance Varoglutamstat in treating Chronic Kidney Disease by targeting QPCT/QPCTL.

                            Product Name : PQ912

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 06, 2025

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Koch Wertpapierhandels GmbH

                            Deal Size : $5.9 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Yorkville

                            Deal Size : $17.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million

                            Details : The financing aims to advance the clinical development of PQ912 (varoglutamstat) is a selective inhibitor of QPCT/QPCTL with therapeutic potential in indications including

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 24, 2025

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Yorkville

                            Deal Size : $17.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Presents Phase 2 Data Supporting Varoglutamstat’s Potential in Kidney Function

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Reports Unique Effects of Varoglutamstat on Kidney Function in Diabetes

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Updates on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program ...

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2023

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimo...

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 23, 2023

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Hauck Aufhäuser Lampe Privatbank AG

                            Deal Size : $26.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

                            Details : Vivoryon intends to use the net proceeds to accelerate the ongoing clinical development of its lead product candidate PQ912 (varoglutamstat), currently in Phase 2 in Europe and the United States for the treatment of patients with Alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 26, 2023

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Hauck Aufhäuser Lampe Privatbank AG

                            Deal Size : $26.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment o...

                            Details : PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 28, 2023

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed

                            Vivoryon Therapeutics

                            Germany arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Nordic Bioscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerat...

                            Details : Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 31, 2022

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Nordic Bioscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth